Overview

BT1718 in Patients With Advanced Solid Tumours.

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This clinical trial is looking at a drug called BT1718 in adult patients with advanced solid tumours. The main aim of the study is to find the maximum dose of BT1718 that can be given safely to patients; learn more about the potential side effects of BT1718 and how they can be treated and also what happens to BT1718 inside the body.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cancer Research UK